Actinium Pharmaceuticals Announces Presentation of Interim Results from MSKCC Phase 1 AML Trial at the American Society of Hematology Meeting

Phase I trial of the targeted α-Particle Nanogenerator 225Ac-Lintuzumab in Acute Myeloid Leukemia.

Newark, NJ (PRWEB) December 11, 2011 -- Actinium Pharmaceuticals, Inc., a company focused on alpha radioimmunotherapy of advanced cancers, announced today that an oral presentation on 225Actinium-Lintuzumab will be given at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition to be held December 10-13, 2011 at the San Diego Convention Center in California. 225Actinium-Lintuzumab is an alpha particle emitter labeled monoclonal antibody currently in clinical studies for treatment of Acute Myeloid Leukemia (AML).

Oral session: Acute Myeloid Leukemia - Therapy, excluding Transplantation: Clinical Studies, Room 30, Monday, December 12, 2011, 04:30 – 6:00 PM PT.
“Phase I Trial of the Targeted α-Particle Nanogenerator 225Ac-Lintuzumab in Acute Myeloid Leukemia”

For more details on the congress, please visit the official congress web site:
http://www.hematology.org/Meetings/Annual-Meeting/

About 225Ac-Lintuzumab
225Actinium-Lintuzumab is a drug construct consisting of the HuM195 (Lintuzumab) monoclonal antibody labeled with an alpha particle emitting radioisotope actinium 225. HuM195 targets the CD33 antigen expressed by most acute myeloid leukemia cells but not present on any non-hematopoetic cells. 225Actinium-Lintuzumab is currently being used in an ongoing Phase I trial. Actinium Pharmaceuticals is in the final stages of preparation for a new Phase I/II trial at multiple clinical centers in the U.S..

About Actinium Pharmaceuticals
Actinium Pharmaceuticals is an oncology focused biotechnology company. The Company’s Alpha Particle Immunotherapy Technology (APIT) couples monoclonal antibodies (mAbs) with alpha particle emitting radioactive isotopes, in particular Actinium 225 and Bismuth 213. (www.actiniumpharmaceuticals.com)

Safe Harbor Statement
This release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein that do not describe historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward looking statements. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

###
Contact Information
Dragan Cicic
dcicic@actiniumpharmaceuticals.com
718 369 7089

Online Web 2.0 Version
You can read the online version of this press release here.